ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022

Rhea-AI Summary

ProKidney Corp. (Nasdaq: PROK) announced it will present five posters on chronic kidney disease (CKD) during the ASN Annual Meeting in Orlando, FL, from November 3-6, 2022. Topics include CKD prevalence, gender differences in progression, and the effects of SGLT2 inhibitors. The company will hold an investor briefing on November 3. The lead product candidate, REACT™, aims to slow CKD progression and has received RMAT designation. CKD affects approximately 75 million people in the U.S. and Europe, with significant healthcare costs associated.

Positive

• ProKidney's lead product, REACT™, has RMAT designation, supporting its Phase 3 clinical program.
• The upcoming presentations at ASN provide visibility and credibility to ProKidney's research.

Negative

• None.

- Company will present five posters discussing REACT and chronic kidney disease during the ASN Annual Meeting, November 3 - 6, 2022

- Investor and analyst scientific briefing to be hosted in Orlando, FL on November 3, 2022

WINSTON-SALEM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters on REACT and CKD at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held November 3-6, 2022, in Orlando, FL.

Details for the poster presentations are as follows:

• Prevalence of Chronic Kidney Disease (CKD): Comparison of Real-World Data (RWD) Sources to the USA National Health and Nutrition Examination Survey (NHANES)
  

Session Title: CKD: Epidemiology, Risk Factors, Prevention – I [PO2201-1]
Session Date, Time: November 3, 2022, from 10:00 AM to 12:00 PM
Poster Board #: TH-PO887

• Selected Renal Cells Self-organize to Form Neo-nephrons and Attenuate Kidney Disease
  

Session Title: Genetics, Development, Regeneration [PO0500]
Session Date, Time: November 4, 2022, from 10:00 AM to 12:00 PM
Poster Board #: FR-PO394

• Gender Differences in Chronic Kidney Disease (CKD) Progression: Real-world Data (RWD) Analysis
  

Session Title: CKD: Epidemiology, Risk Factors, Prevention – II [PO2201-2]
Session Date, Time: November 4, 2022, from 10:00 AM to 12:00 PM
Poster Board #: FR-PO905

• SGLT2i Prescribers among Chronic Kidney Disease (CKD) Patients: Trends in Real-World Data (RWD)
  Session Title: CKD: Epidemiology, Risk Factors, Prevention – II [PO2201-2]
  Session Date, Time: November 4, 2022, from 10:00 AM to 12:00 PM
  Poster Board #: FR-PO904
  
• Gene Ontology Reveals Potentially Unique Mechanism of Action Underlying Selected Renal Cells Bioactivity
  Session Title: CKD: Pathobiology – II [PO2203-2]
  Session Date, Time: November 5, 2022, from 10:00 AM to 12:00 PM
  Poster Board #: SA-PO957
  

Abstracts can be accessed online at https://www.asn-online.org/education/kidneyweek/.

ProKidney also announced today that it will host an investor and analyst scientific briefing, followed by a reception, the evening of November 3, 2022, in Orlando, FL. To register for the event, or for additional information, please contact Dr. Glenn Schulman at glenn.schulman@prokidney.com. Following the event, a copy of the presentation slides will be available on the Company’s website at https://investors.prokidney.com/news-events/events-and-presentations.

About ProKidney

ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD patients, Stage 3b - 4, is a key target population for REACT therapy. REACT has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program that launched in January 2022. For more information, visit www.prokidney.com.

About CKD

There are no therapies that effectively reverse late-stage CKD. CKD is a serious diagnosis with significant morbidity and mortality. Notably, the 5-year mortality of newly diagnosed Stage 4 CKD is higher than that of newly diagnosed non-metastatic cancer. CKD most often presents as a progressive decline in kidney function, ultimately resulting in the failure of the kidneys and the need for renal replacement therapy, such as hemodialysis or kidney transplant. One in three Americans is at risk for CKD which currently affects approximately 75 million people in the United States and Europe and over 400 million across Asia. CKD is among the largest single expenses incurred by the U.S. health care system.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the combined company’s expectations with respect to financial results, future performance, development and commercialization of products, if approved, the potential benefits and impact of the combined company’s products, if approved, potential regulatory approvals, anticipated financial impacts and other effects of the business combination on the combined company’s business, and the size and potential growth of current or future markets for the combined company’s products, if approved. Most of these factors are outside of the combined company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the combined company’s Class A ordinary shares on the Nasdaq following the business combination; the inability to implement business plans, forecasts, and other expectations and to recognize the anticipated benefits of the business combination or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the combined company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the inability of the combined company to raise financing in the future; the inability of the combined company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the combined company to identify, in-license or acquire additional technology; the inability of combined company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the combined company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the combined company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the combined company’s financial performance; the combined company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the impact of COVID-19 or geo-political conflict such as the war in Ukraine on the combined company’s business; and other risks and uncertainties indicated from time to time in the proxy statement relating to the business combination, including those under “Risk Factors” therein, and in the combined company’s other filings with the Securities and Exchange Commission. The combined company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The combined company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Information

Investors & Media
Glenn Schulman, PharmD, MPH
SVP, Investor Relations
glenn.schulman@prokidney.com

FAQ

What is the significance of ProKidney's presence at the ASN Annual Meeting 2022?

ProKidney is presenting five posters on chronic kidney disease (CKD), enhancing its visibility in the medical community.

What topics will ProKidney present at the ASN Annual Meeting?

Topics include CKD prevalence, gender differences in progression, and trends in SGLT2 inhibitor prescribing.

When is the investor briefing hosted by ProKidney?

The investor and analyst scientific briefing will take place on November 3, 2022.

What is REACT™ and its relevance to ProKidney?

REACT™ is ProKidney's lead product aimed at slowing CKD progression, which has received Regenerative Medicine Advanced Therapy designation.

How many people are affected by CKD in the U.S. and Europe?

CKD affects approximately 75 million people in the United States and Europe.